Amylin Pharmaceuticals (AMLN) Reports Q1 Loss of 24c, Misses by 1c

Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) reported Q1 EPS of ($0.24), $0.01 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $152.7 million versus the consensus estimate of $156.73 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies Financial stock slips 3% as Fixed Income, Asset Management revenues fall
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance
• Scholastic Corp (SCHL) Misses Q1 EPS by 23c